🍽️ leflunomide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Rheumatoid Arthritis (RA): Leflunomide is FDA-approved for the treatment of rheumatoid arthritis in adults. It helps to relieve symptoms such as joint pain, swelling, and stiffness and slows down the progression of joint damage caused by RA. Leflunomide is often used as a first-line or adjunct therapy in the management of RA, either alone or in combination with other DMARDs or biologic agents.

  2. Psoriatic Arthritis: Leflunomide may also be used off-label for the treatment of psoriatic arthritis, a type of arthritis that affects some people with psoriasis, a chronic skin condition characterized by red, scaly patches on the skin. Leflunomide can help reduce joint inflammation and symptoms associated with psoriatic arthritis.

  3. Ankylosing Spondylitis: Ankylosing spondylitis is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints. While leflunomide is not typically a first-line treatment for ankylosing spondylitis, it may be used off-label in some cases, especially when other treatments have been ineffective or poorly tolerated.

  4. Juvenile Idiopathic Arthritis (JIA): Leflunomide is sometimes used off-label in the treatment of juvenile idiopathic arthritis (formerly known as juvenile rheumatoid arthritis) in children and adolescents who have not responded adequately to other therapies. However, the safety and efficacy of leflunomide in pediatric patients are not well-established.

  5. Other Autoimmune Conditions: Leflunomide may be considered off-label for the treatment of other autoimmune conditions characterized by inflammation, such as systemic lupus erythematosus (SLE) or autoimmune hepatitis. However, its use in these conditions is less common, and the evidence supporting its efficacy may be limited.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of leflunomide,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by leflunomide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Segatella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Akkermansia genus Decreases 📓 Source Study
Lacrimispora genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Agathobacter rectalis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Roseburia intestinalis species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Clostridioides difficile species Decreases 📓 Source Study Colitis
Lachnospira eligens species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of leflunomide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.1 -0.1
ADHD 3 0.5 5
Age-Related Macular Degeneration and Glaucoma 0.9 0.3 2
Allergic Rhinitis (Hay Fever) 0.5 0.3 0.67
Allergies 3 1 2
Allergy to milk products 0.2 0.3 -0.5
Alopecia (Hair Loss) 1 1
Alzheimer's disease 2.1 5.4 -1.57
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.2 0.4 7
Ankylosing spondylitis 1.7 0.5 2.4
Anorexia Nervosa 0.3 1.3 -3.33
Antiphospholipid syndrome (APS) 1 1
Asthma 0.2 1.3 -5.5
Atherosclerosis 0.3 2.1 -6
Atrial fibrillation 2.3 1.1 1.09
Autism 6.3 6.4 -0.02
Barrett esophagus cancer 0.1 0.1
Biofilm 0 0
Bipolar Disorder 0.5 1 -1
Brain Trauma 0.3 0.7 -1.33
Cancer (General) 0.4 1 -1.5
Carcinoma 1.9 1.8 0.06
Celiac Disease 1.6 2.2 -0.38
Cerebral Palsy 0.4 0.8 -1
Chronic Fatigue Syndrome 2.6 7 -1.69
Chronic Kidney Disease 1.6 2.1 -0.31
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 0.1 1.1 -10
Chronic Urticaria (Hives) 0.1 1.6 -15
Coagulation / Micro clot triggering bacteria 0.3 0.5 -0.67
Colorectal Cancer 2.2 0.6 2.67
Constipation 1.3 0.5 1.6
Coronary artery disease 0.6 0.7 -0.17
COVID-19 6.4 10.3 -0.61
Crohn's Disease 4.5 5 -0.11
cystic fibrosis 0.7 -0.7
deep vein thrombosis 0.4 -0.4
Depression 5.3 6.7 -0.26
Dermatomyositis 0.1 -0.1
Eczema 0.1 0.8 -7
Endometriosis 1.6 0.8 1
Eosinophilic Esophagitis 0 0.1 0
Epilepsy 1.6 2.1 -0.31
Fibromyalgia 2.4 2.4 0
Functional constipation / chronic idiopathic constipation 3.7 3.4 0.09
gallstone disease (gsd) 1 0.5 1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.6 0.2 7
Generalized anxiety disorder 0.1 0.9 -8
Gout 0.5 -0.5
Graves' disease 0.8 1.2 -0.5
Halitosis 0.4 0.4
Hashimoto's thyroiditis 2.5 0.3 7.33
Hidradenitis Suppurativa 0 0.1 0
High Histamine/low DAO 0.4 0.1 3
hypercholesterolemia (High Cholesterol) 0.4 0.4 0
hyperglycemia 0.1 1.3 -12
Hyperlipidemia (High Blood Fats) 0.5 0.2 1.5
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 1 4.2 -3.2
Hypothyroidism 0.7 -0.7
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 2.7 -2.7
Inflammatory Bowel Disease 1.5 5.8 -2.87
Insomnia 0.3 0.9 -2
Intelligence 1.2 0.5 1.4
Intracranial aneurysms 0.6 0.2 2
Irritable Bowel Syndrome 1.6 3.8 -1.37
Liver Cirrhosis 2.8 2 0.4
Long COVID 4.8 5 -0.04
Low bone mineral density 1.1 -1.1
Lung Cancer 0 1 0
Mast Cell Issues / mastitis 0.5 -0.5
ME/CFS with IBS 0.1 2.4 -23
ME/CFS without IBS 0.3 2 -5.67
Menopause 0.8 0.8
Metabolic Syndrome 4.2 6.5 -0.55
Mood Disorders 6.6 6.7 -0.02
multiple chemical sensitivity [MCS] 0.3 0.1 2
Multiple Sclerosis 1.8 3.5 -0.94
Multiple system atrophy (MSA) 1.6 0.2 7
neuropathic pain 1.7 -1.7
Neuropathy (all types) 0.3 0.3
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.3 3.1 -1.38
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 6.9 3.7 0.86
obsessive-compulsive disorder 4.3 4.1 0.05
Osteoarthritis 0.5 0.5
Osteoporosis 0.4 0.7 -0.75
pancreatic cancer 0.4 0.4
Parkinson's Disease 1.8 3 -0.67
Polycystic ovary syndrome 1.4 1.1 0.27
Postural orthostatic tachycardia syndrome 0.5 -0.5
Premenstrual dysphoric disorder 0.4 0.3 0.33
primary biliary cholangitis 0.5 0.9 -0.8
Psoriasis 2.6 2.5 0.04
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.7 3.2 0.16
Rosacea 1.1 0.4 1.75
Schizophrenia 3.5 1 2.5
scoliosis 0.5 0.5 0
Sjögren syndrome 1.6 2.3 -0.44
Sleep Apnea 0.6 1.3 -1.17
Slow gastric motility / Gastroparesis 0.3 0.1 2
Small Intestinal Bacterial Overgrowth (SIBO) 0 0.1 0
Stress / posttraumatic stress disorder 1.7 1.9 -0.12
Systemic Lupus Erythematosus 2.4 1.2 1
Tic Disorder 1.2 1.3 -0.08
Tourette syndrome 0.2 0.2 0
Type 1 Diabetes 3.1 1.5 1.07
Type 2 Diabetes 5 5.3 -0.06
Ulcerative colitis 1.3 5.1 -2.92
Unhealthy Ageing 4 2.3 0.74

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]